Abstract
Bisphosphonates are the most potent and effective inhibitors of bone resorption in clinical use, with good efficacy and tolerability in reducing fracture risk, in increasing bone mineral density and in reducing biochemical markers of bone turnover. Clinical trials indicate that bisphosphonates can reduce the incidence of fractures related to postmenopausal osteoporosis but adherence to bisphosphonate therapy remains suboptimal. Long-term adherence with bisphosphonates is required for optimal and sustained therapeutic benefits in postmenopausal osteoporosis. Simplifying dosing by reducing the frequency and/or number of administrations is an often-used strategy for enhancing adherence, especially with new compounds with high anti-resorptive potency and favourable bone-binding properties
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
